Memorial Sloan Kettering Cancer Center

A machine learning model combining clinical and genomic data more accurately predicted outcomes for HR-positive, HER2-negative metastatic breast cancer patients treated with CDK4/6 inhibitors compared to models using clinical or genomic data alone, according to a study presented at SABCS 2024.

In early December, the FDA approved Bizengri for advanced NRG1 fusion-positive NSCLC and pancreatic cancer, and expanded Imfinzi's use to treat limited-stage SCLC after chemotherapy and radiation, marking significant advancements in lung cancer treatment.

Experimental hormone therapy pill imlunestrant shows promise in extending lives of women with advanced breast cancer, particularly those with ESR1 gene mutations. Imlunestrant, a SERD, improved progression-free survival and was more effective when combined with Verzenio, offering a potential all-oral targeted therapy option.

Experimental hormone therapy pill imlunestrant shows promise in extending lives of women with advanced breast cancer, particularly those with ESR1 gene mutations. The drug, a selective estrogen receptor degrader, improved progression-free survival and was more effective when combined with Verzenio, offering a potential all-oral targeted therapy option.

Revumenib (Revuforj) received FDA approval in Nov 2024 for KMT2A-rearranged relapsed/refractory acute leukemia, based on AUGMENT-101 study showing 21.2% CR/CRh rate. 14% achieved transfusion independence, highlighting potential to improve remission rates and quality of life. Revumenib's ability to clear blasts offers patients opportunity for allogeneic stem cell transplant.

The FDA accelerated approval of zanidatamab-hrii (Ziihera) for previously treated HER2-positive biliary tract cancer fills a treatment gap. The phase 2b HERIZON-BTC-01 trial supported the approval with a 52% objective response rate and median duration of response of 14.9 months. Zanidatamab, a novel bispecific HER2-targeted antibody, offers a new treatment option for this difficult-to-treat disease, with ongoing evaluations in frontline therapy.

Absci Corp. announced progress in its AI-driven drug creation programs, including ABS-201 for androgenic alopecia, ABS-101 for anti-TL1A, ABS-301 for immuno-oncology, and ABS-501 for anti-HER2. The company also highlighted a breakthrough in designing an antibody targeting the HIV 'caldera' region, potentially aiding universal HIV vaccine development.

Eli Lilly's Phase III EMBER-3 study showed imlunestrant reduced disease progression or death risk by 38% in advanced breast cancer patients with ESR1 mutations, with 5.5 months PFS vs. 3.8 months SOC. Combined with Verzenio, it reduced progression risk by 43% in all patients. Imlunestrant, an oral SERD, addresses injection-related issues of fulvestrant.

Absci announced updates on its AI-driven drug creation programs, including ABS-201 for androgenic alopecia, ABS-101 for anti-TL1A, ABS-301 for immuno-oncology, and ABS-501 for anti-HER2. The company also highlighted a breakthrough in designing antibodies targeting the HIV 'caldera' region, potentially aiding universal HIV vaccine development.